The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030, predicts Roots Analysis

The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market.

Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs. There are more than 150 manufacturing facilities, with microbial fermentation capabilities, worldwide; of these, 43% are in Europe, followed by North America (31%). The growth trend of outsourcing microbial manufacturing operations is evident from the rise in recent partnership activity, as well as expansion initiatives undertaken by CMOs to meet the growing demand for novel biologics.


To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this -


The USD 9.3 billion (by 2030) financial opportunity within the microbial biomanufacturing market has been analyzed across the following segments:

  • Type of Product
  • API
  • FDF


  • Type of Biologic
  • Proteins
  • Enzymes
  • Growth Hormones
  • Antibody based Drugs
  • Others (plasmid DNA, probiotics, microbiome-based biologics)


  • Type of Microbial Expression System
  • Bacteria
  • Yeast
  • Others (Algae and fungi)


  • Scale of Operation
  • Commercial
  • Preclinical / Clinical


  • Type of End User
  • Small Companies
  • Mid-sized Companies
  • Large / Very Large Companies


  • Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific
  • Middle East and North Africa
  • Latin America


The Microbial Contract Biomanufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • AGC Biologics
  • Aldevron
  • BioVectra
  • EirGenix
  • Etinpro
  • Eurogentec
  • Northway Biotechpharma
  • Ology Bioservices
  • Porton Biopharma
  • Stelis Biopharma


Table of Contents


  1. Preface

    2. Executive Summary

  2. Introduction
  3. Market Landscape
  4. Company Competitiveness Analysis


  1. Company Profiles
  2.  Recent Partnerships
  3. Recent Expansions
  4. Microbial fermentation technology platforms
  5. Assessment of Relative Competition and Growth
  6. Make versus Buy Decision Making Framework


  1. Big Pharma Initiatives in Microbial Biomanufacturing


  1. Case study: comparison of small molecule and large


  1. Market Sizing and Opportunity Analysis
  2. Impact of covid-19 pandemic on microbial contract biomanufacturing market


  1. Swot Analysis


  1. Conclusion Appendix 3: List of Companies and Organizations
  2. Interview Transcripts


  1. Appendix 1: Tabulated Data


  1. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at


Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

Facebook -

LinkedIn -

Twitter -

Medium -

Pinterest -

Quora -